Skip to main content
EJNMMI Radiopharmacy and Chemistry
Fig. 1 | EJNMMI Radiopharmacy and Chemistry

Fig. 1

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Fig. 1

a. SDS-PAGE analysis of panitumumab IgG and F(ab´)2 under non-reducing (lanes 1, 2, respectively) or reducing (lanes 3, 4, respectively) conditions on a 7.5% Tris/Glycine mini-gel stained with Coomassie blue. b. SE-HPLC chromatogram of [64Cu]Cu-DOTA-panitumumab F(ab´)2 analyzed on a BioSep SEC-4000 column eluted with NaH2PO4 buffer, pH 7.0 at a flow rate of 0.5 mL/min with UV detection at 280 nm. C. SE-HPLC chromatogram of [64Cu]Cu-DOTA-panitumumab F(ab´)2 with radioactivity detection. Integration of the peak with tR = 15.21 mins on the chromatogram with UV detection indicated a purity for DOTA-panitumumab F(ab´)2 of 96.1%. Integration of the peak with tR = 15.38 mins on the chromatogram with radioactivity detection indicated a radiochemical purity for [64Cu]Cu-DOTA-panitumumab F(ab´)2 of 96.3%. There is a slight delay between detection of the peak by the radioactivity detector compared to the UV detector since these detectors are in sequence

Back to article page